GSTP1 Polymorphism and Survival in Colorectal Cancer
Author Information
Author(s): Kweekel D M, Koopman M, Antonini N F, Van der Straaten T, Nortier J W R, Gelderblom H, Punt C J A, Guchelaar H-J
Primary Institution: Leiden University Medical Center
Hypothesis
The GSTP1 Ile105Val polymorphism affects progression-free survival in metastatic colorectal cancer patients treated with irinotecan.
Conclusion
Patients with the Ile/Ile genotype do not benefit from the addition of irinotecan to capecitabine treatment.
Supporting Evidence
- Patients with the Ile/Ile genotype showed similar PFS with CAPIRI and CAP.
- Median PFS was 2.7 months longer in Val-allele carriers treated with CAPIRI compared to CAP.
- Toxicity did not differ significantly among genotypes.
Takeaway
This study found that some patients with a specific gene variant do better with a certain cancer treatment, while others do not benefit at all.
Methodology
The study analyzed the association of GSTP1 genotype with treatment outcomes in a randomized phase III trial involving 267 metastatic colorectal cancer patients.
Potential Biases
The study may have selection bias due to the timing of sample collection and the characteristics of the patients.
Limitations
Samples were obtained at a median of 5 months after inclusion, which may introduce selection bias.
Participant Demographics
The majority of patients were of Caucasian descent, with a median age of 61.5 years.
Statistical Information
P-Value
0.005
Confidence Interval
95% CI: 7.6–8.8
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website